Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of MK-6916 on the Pharmacokinetics of Midazolam and Rosuvastatin
NCT07862621Phase 1Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Primary completion
- Feb 2027
01
Overview
Phase 1, open-label, single-arm trial of MK-6916 in pain, sponsored by Merck & Co. Primary endpoint: Area Under the Concentration-Time Curve From Time 0 to Infinity. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
MK-6916
03
Conditions
pain
Beyond the preview
Go deeper on NCT07862621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862621.